IBDEI0YC ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,16125,1,3,0)
 ;;=3^Hypersplenism
 ;;^UTILITY(U,$J,358.3,16125,1,4,0)
 ;;=4^D73.1
 ;;^UTILITY(U,$J,358.3,16125,2)
 ;;=^60330
 ;;^UTILITY(U,$J,358.3,16126,0)
 ;;=D57.819^^61^723^5
 ;;^UTILITY(U,$J,358.3,16126,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16126,1,3,0)
 ;;=3^Sickle-Cell Disorders w/ Crisis,Unspec
 ;;^UTILITY(U,$J,358.3,16126,1,4,0)
 ;;=4^D57.819
 ;;^UTILITY(U,$J,358.3,16126,2)
 ;;=^5002320
 ;;^UTILITY(U,$J,358.3,16127,0)
 ;;=D57.3^^61^723^7
 ;;^UTILITY(U,$J,358.3,16127,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16127,1,3,0)
 ;;=3^Sickle-Cell Trait
 ;;^UTILITY(U,$J,358.3,16127,1,4,0)
 ;;=4^D57.3
 ;;^UTILITY(U,$J,358.3,16127,2)
 ;;=^5002313
 ;;^UTILITY(U,$J,358.3,16128,0)
 ;;=D57.20^^61^723^8
 ;;^UTILITY(U,$J,358.3,16128,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16128,1,3,0)
 ;;=3^Sickle-Cell/Hb-C Disease w/o Crisis
 ;;^UTILITY(U,$J,358.3,16128,1,4,0)
 ;;=4^D57.20
 ;;^UTILITY(U,$J,358.3,16128,2)
 ;;=^330080
 ;;^UTILITY(U,$J,358.3,16129,0)
 ;;=D56.8^^61^723^9
 ;;^UTILITY(U,$J,358.3,16129,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16129,1,3,0)
 ;;=3^Thalassemias
 ;;^UTILITY(U,$J,358.3,16129,1,4,0)
 ;;=4^D56.8
 ;;^UTILITY(U,$J,358.3,16129,2)
 ;;=^5002305
 ;;^UTILITY(U,$J,358.3,16130,0)
 ;;=D57.40^^61^723^6
 ;;^UTILITY(U,$J,358.3,16130,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16130,1,3,0)
 ;;=3^Sickle-Cell Thalassemia w/o Crisis
 ;;^UTILITY(U,$J,358.3,16130,1,4,0)
 ;;=4^D57.40
 ;;^UTILITY(U,$J,358.3,16130,2)
 ;;=^329908
 ;;^UTILITY(U,$J,358.3,16131,0)
 ;;=C91.01^^61^724^20
 ;;^UTILITY(U,$J,358.3,16131,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16131,1,3,0)
 ;;=3^Lymphoblastic Leukemia,Acute,In Remission
 ;;^UTILITY(U,$J,358.3,16131,1,4,0)
 ;;=4^C91.01
 ;;^UTILITY(U,$J,358.3,16131,2)
 ;;=^5001763
 ;;^UTILITY(U,$J,358.3,16132,0)
 ;;=C91.00^^61^724^21
 ;;^UTILITY(U,$J,358.3,16132,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16132,1,3,0)
 ;;=3^Lymphoblastic Leukemia,Acute,Not in Remission
 ;;^UTILITY(U,$J,358.3,16132,1,4,0)
 ;;=4^C91.00
 ;;^UTILITY(U,$J,358.3,16132,2)
 ;;=^5001762
 ;;^UTILITY(U,$J,358.3,16133,0)
 ;;=C92.41^^61^724^41
 ;;^UTILITY(U,$J,358.3,16133,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16133,1,3,0)
 ;;=3^Promyleocytic Leukemia,Acute,In Remission
 ;;^UTILITY(U,$J,358.3,16133,1,4,0)
 ;;=4^C92.41
 ;;^UTILITY(U,$J,358.3,16133,2)
 ;;=^5001802
 ;;^UTILITY(U,$J,358.3,16134,0)
 ;;=C92.01^^61^724^32
 ;;^UTILITY(U,$J,358.3,16134,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16134,1,3,0)
 ;;=3^Myeloblastic Leukemia,Acute,In Remission
 ;;^UTILITY(U,$J,358.3,16134,1,4,0)
 ;;=4^C92.01
 ;;^UTILITY(U,$J,358.3,16134,2)
 ;;=^5001790
 ;;^UTILITY(U,$J,358.3,16135,0)
 ;;=C92.51^^61^724^35
 ;;^UTILITY(U,$J,358.3,16135,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16135,1,3,0)
 ;;=3^Myelomonocytic Leukemia,Acute,In Remission
 ;;^UTILITY(U,$J,358.3,16135,1,4,0)
 ;;=4^C92.51
 ;;^UTILITY(U,$J,358.3,16135,2)
 ;;=^5001805
 ;;^UTILITY(U,$J,358.3,16136,0)
 ;;=C91.11^^61^724^24
 ;;^UTILITY(U,$J,358.3,16136,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16136,1,3,0)
 ;;=3^Lymphocytic B-Cell Type Leukemia,Chr,In Remission
 ;;^UTILITY(U,$J,358.3,16136,1,4,0)
 ;;=4^C91.11
 ;;^UTILITY(U,$J,358.3,16136,2)
 ;;=^5001766
 ;;^UTILITY(U,$J,358.3,16137,0)
 ;;=C91.10^^61^724^25
 ;;^UTILITY(U,$J,358.3,16137,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16137,1,3,0)
 ;;=3^Lymphocytic B-Cell Type Leukemia,Chr,Not in Remission
 ;;^UTILITY(U,$J,358.3,16137,1,4,0)
 ;;=4^C91.10
 ;;^UTILITY(U,$J,358.3,16137,2)
 ;;=^5001765
 ;;^UTILITY(U,$J,358.3,16138,0)
 ;;=C92.11^^61^724^33
 ;;^UTILITY(U,$J,358.3,16138,1,0)
 ;;=^358.31IA^4^2
